The frequency of Cosentyx (secukinumab) adjustment is determined by several factors, primarily the patient's response to treatment and the specific medical condition being addressed.

Secukinumab is a human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), a molecule involved in the inflammatory response of several diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

The dosage and administration frequency of Cosentyx are typically determined by the patient's body weight and the specific medical condition being treated. For instance, in psoriasis, the recommended dosage is 300 mg at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks [2]. However, in psoriatic arthritis and ankylosing spondylitis, the recommended dosage is 150 mg at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks [2].

The frequency of Cosentyx adjustment is primarily based on the patient's clinical response to treatment. If a patient does not respond adequately to the initial dosing regimen, the dosage may be increased or the administration frequency may be adjusted [3]. For example, in patients with psoriasis who have an inadequate response to 300 mg every 4 weeks, the dosage may be increased to 300 mg every 2 weeks [3].

In addition, the patient's renal and hepatic function, as well as any concomitant medications, may also impact the frequency of Cosentyx adjustment [4]. For instance, in patients with severe renal impairment or end-stage renal disease, the dosing interval should be increased to every 8 weeks [4].

In summary, the frequency of Cosentyx adjustment is determined by several factors, including the patient's response to treatment, the specific medical condition being addressed, the patient's renal and hepatic function, and any concomitant medications.

Sources:
[1] DrugPatentWatch.com. Cosentyx (secukinumab) Drug Profile. <https://www.drugpatentwatch.com/drugs/cosentyx>.
[2] Novartis Pharmaceuticals Corporation. Cosentyx (secukinumab) Prescribing Information. January 2022. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
[3] National Psoriasis Foundation. Secukinumab (Cosentyx). <https://www.psoriasis.org/treatments/systemics/biologics/secukinumab-cosentyx>.
[4] UpToDate. Secukinumab: Indications, dosing, and side effects in clinical practice. <https://www.uptodate.com/contents/secukinumab-indications-dosing-and-side-effects-in-clinical-practice>.